|
Sebkova 2012
|
Czech Republic
|
Retro
|
CDAI <150, no mucosal ulcerations
|
–
|
60
|
IFX† or ADA‡
|
IMM§ (not specified, used in 30/60)
|
1 year
|
Yes (17/60)
|
|
Vadan 2012
|
Romania
|
Pro
|
CDAI <150, no mucosal ulcerations
|
–
|
49*
|
IFX†
|
IMM§ (5/49)
|
1 year
|
No
|
|
Vadan 2013
|
Romania
|
Pro
|
CDAI <150, no mucosal ulcerations
| |
49*
|
IFX†
|
IMM§ (5/49)
|
6 months
|
No
|
|
De Vos 2013
|
Belgium
|
Pro
|
Partial Mayo <3, endo Mayo 0
|
87
|
–
|
IFX†
|
AZA¶ (60/87)
|
1 year
|
No
|
|
Molander 2013
|
Finland
|
Retro
|
No clinical symptoms, SES-CD 0–2, endo Mayo 0–1
|
69
|
183
|
IFX† or ADA‡
|
AZA¶ (140/252), 6MP (23/252), MTX (22/252)
|
2 year
|
Not specified
|
|
Dai 2014
|
China
|
Pro
|
CDAI <150, Mayo <2, SES-CD 0–3, endo Mayo 0
|
107
|
109
|
IFX†
|
IMM§ (66/109 CD, 34/107 UC)
|
1 year
|
Yes (17 CD, 3 UC)
|
|
Echarri 2015
|
Spain
|
Pro
|
HBI <5, SES-CD 0–2
|
–
|
64
|
ADA‡
|
AZA¶ (44/68), steroids (56/68)
|
6 months, 1 year, 2 year
|
No
|
|
Yu 2015
|
China
|
Retro
|
CDAI <150, SES-CD 0–2
|
–
|
106
|
IFX†
|
AZA¶ (49/106)
|
8 weeks
|
No
|
|
Magro 2016
|
Portugal
|
Pro
|
Mayo 0–2, endo Mayo 0–1, Geboe’s score <4
|
20
|
–
|
IFX†
|
AZA¶ (17/20)
|
8 weeks, 6 month, 1 year
|
No
|
|
Pineton de Chambrun 2016
|
France
|
Retro
|
Clinical physician assessment, no ulcerations
|
–
|
67
|
IFX†
|
AZA¶ (26/67)
|
2 year
|
No
|
|
Prymak 2016
|
Ukraine
|
Pro
|
CAI and UCEIS (not defined)
|
51
|
–
|
IFX†
|
Mesalamine + steroids (25/51)
|
8 weeks
|
No
|
|
Zhang 2016
|
China
|
Pro
|
CDAI <150, no ulcerations
|
–
|
22
|
IFX†
|
None
|
6 month, 1 year, 2 year
|
No
|
|
Kaymak 2018
|
Switzerland
|
Retro
|
HBI <5 or CDAI <150, Fcal <150 × 2 years, no ulcerations (endoscopic and histologically)
|
–
|
109
|
IFX†
|
Not specified; steroid refractory
|
2 year
|
Yes (11/109 prior ADA)
|
|
Kumar 2018
|
UK
|
Retro
|
CR + ER (undefined)
|
56
|
–
|
Golimumab
|
IMM§ (36/56)
|
1 year
|
Not specified
|
|
Munoz-Villafranca 2018
|
Spain
|
Pro
|
pMayo 0–2, endo Mayo 0–1
|
53
|
–
|
ADA‡
|
IMM§ (38/53)
|
8 weeks, 1 year
|
No
|
